Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ratings.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

While MRK stock looks promising, investing in a single stock can be risky. On the other hand, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of over the ...

Japan 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y4.72 bln Y4.46 bln Operating Profit (Y458.00 mln) (Y379.00 mln) Pretax Profit (Y313.00 mln) (Y332.00 mln) Net Profit (Y182.00 mln) (Y266.00 mln ...

MRK stock, with -14% returns since the beginning of 2024, has underperformed the S&P 500 index, up 27%. Merck’s HPV vaccine – Gardasil – is facing a challenge in China amid lower demand.